Updated October 2026 · Written and maintained by the Progression Agency strategy team
Pharma SEO is organic search work for prescription drug and therapy brands: making sure the patients, caregivers and healthcare professionals who search for a condition or a treatment find accurate, approved pages, written and structured so they survive medical, legal and regulatory review. We work with brand and digital teams at pharmaceutical and biopharma manufacturers, and with the agencies that serve them, and the output is more qualified visits to product, disease-awareness, HCP and corporate pages. Progression Agency is based in New York City and works with clients across the United States and worldwide.
On this page · 19 sections
- What is pharma SEO, and what does it not cover?
- Who do pharma companies sell to, and who should their search content reach?
- Branded and unbranded search: two content tracks under different rules
- Pharmaceutical SEO services: what the program includes
- How SEO work moves through medical, legal and regulatory review
- Title tags, snippets and safety information in search results
- Indication, safety information and prescribing information page patterns
- Structured data for pharmaceutical and medical content
- E-E-A-T for drug and disease content: reviewers, references and dates
- HCP-gated content, consent banners and other technical issues on regulated sites
- International pharmaceutical SEO: country labels, hreflang and local rules
- Clinical trial, pipeline and publication pages
- Pharma SEO compliance: the rules we work inside
- AI answers: how patients, clinicians and analysts ask assistants about medicines
- Measuring organic performance for a regulated brand
- How long does SEO take for a pharma brand?
- How much do pharmaceutical SEO services cost?
- How to choose a pharmaceutical SEO company
- Related services for pharmaceutical brands
The short answerPharmaceutical SEO starts with an intent map by audience, because a patient, a prescriber and a formulary reviewer type different searches and are allowed to see different pages. From there the work is technical fixes, branded and unbranded content kept on separate tracks, title tags and snippets that carry no claim reviewers have not approved, medical structured data and reporting by audience with no health data in analytics. Every change moves through your medical, legal and regulatory review as one packet. Technical fixes show within weeks; new pages depend on review cycles and usually compound over two to three quarters. Our published SEO retainers start at $1,500 a month.
Rules and guidance are described as published in October 2026 and can change; nothing on this page is legal or regulatory advice, and your reviewers decide what each market allows. Prices are Progression’s own published SEO retainers and project prices; a quote follows a written scope.
What is pharma SEO, and what does it not cover?
It is the search work that gets approved pharmaceutical content found: technical health of brand and corporate sites, content mapped to each audience, structured data and measurement. It is not paid media, not AI-answer work on its own and not branding, and each of those has its own page here.
Who hires a pharmaceutical SEO agency
Brand directors who see organic traffic flatten after launch, digital leads at manufacturers running dozens of product and awareness domains, medical affairs teams that want HCP content found, and healthcare agencies that need a search specialist inside their own review process.
Where this page stops
Paid search and programmatic campaigns sit with our team for paid campaigns on pharma brands; visibility in ChatGPT, Gemini and other assistants sits with AEO for pharma; names and identity sit with our pharma branding agency. B2B marketing for research tools, CROs and lab suppliers is covered by our life sciences marketing agency page.
Why SEO for pharmaceutical companies is its own discipline
Search is where patients and clinicians go before and after a conversation with each other. Third-party health sites and forums answer those searches when a brand’s own approved pages cannot be found or cannot be read by a crawler.
Who do pharma companies sell to, and who should their search content reach?
Manufacturers sell mostly through distributors that supply pharmacies, their medicines are prescribed by clinicians, and payers and pharmacy benefit managers decide coverage, while patients and caregivers make many of the searches. Pharmaceutical SEO has to serve every one of those audiences, each with its own page types and rules.
| Audience | What they search for | Page type that answers | Access |
|---|---|---|---|
| Patients | Symptoms, diagnosis, treatment options, what to expect | Disease-awareness hub, branded patient site | Public |
| Caregivers | How to help, daily routines, support programs | Caregiver sections, program enrollment pages | Public |
| Prescribers | Mechanism, dosing, trial results, safety profile | HCP site with prescribing information | Often behind an HCP confirmation |
| Pharmacists | Storage, handling, dispensing details | HCP resources, product information pages | Often behind an HCP confirmation |
| Payers and access teams | Coverage evidence, outcomes, value | Access and reimbursement pages, dossiers on request | Mixed |
| Investors and press | Pipeline, approvals, results, leadership | Corporate newsroom and pipeline pages | Public |
| Clinical trial candidates | Studies near them, eligibility | Trial listings and study pages | Public |
Who should pharmaceutical companies market to first?
Usually the audience whose decision the brand depends on: prescribers for a specialist therapy, patients for a condition people often leave untreated, payers for a product facing coverage hurdles. The SEO plan follows that priority instead of trying to win every search at once.
Patients and caregivers search differently
Patients describe what they feel; caregivers describe what they see and what they have to manage. Pages that answer both, with plain language and a clear next step, earn more of the searches that start long before a prescription.
Clinicians search for precision
Prescribers and pharmacists use clinical terms, generic names and trial acronyms, and they expect to reach the data quickly. Slow verification screens and PDF-only content lose them to reference sites.
Branded and unbranded search: two content tracks under different rules
Branded pages name a product and must carry its indication and safety information; unbranded pages educate about a condition without naming or implying a product. We plan, write and link the two tracks separately so neither puts the other at risk.
| Content type | Names a product? | What has to accompany it | Typical search role |
|---|---|---|---|
| Branded product page | Yes | Indication, safety information in balance with benefits, prescribing information | Product name and treatment searches |
| Reminder-style page | Yes, name only | No representation about the product or suggested use | Rare on the web; handled by reviewers case by case |
| Disease-awareness page | No | Condition education only; sponsor named as reviewers decide | Symptom, diagnosis and condition searches |
| HCP clinical page | Yes | Full prescribing information and the same balance rules | Mechanism, dosing and trial searches |
| Corporate pipeline page | Investigational names | No claims of safety or effectiveness before approval | Company and pipeline searches |
| Patient support page | Yes | Program terms and the product’s safety information | Copay, enrollment and support searches |
What the US rules say about product claims
Under 21 CFR 202.1, prescription drug advertisements must present a true brief summary of side effects, contraindications and effectiveness, may not recommend uses outside the approved labeling, and fail if they lack fair balance between risk and benefit information. Brand pages are written inside those rules from the first draft.
Reminder pages and their limits
FDA’s OPDP frequently asked questions state that reminder advertisements cannot make a representation about the product or suggest a use for it. Most brand sites have no page of this kind; we raise it only when reviewers ask.
Keeping disease-awareness pages unbranded
Awareness content wins the earliest searches, so it is often a large traffic opportunity. It stays useful by staying neutral: no product name, no product imagery, no wording that points to one treatment, and links to the product site only where reviewers approve them.
Pharmaceutical SEO services: what the program includes
The program combines a technical audit, audience research, content on both tracks, medical structured data, review packets and reporting. Every deliverable is shaped to pass through your reviewers rather than around them.
| Workstream | What we do | What you receive |
|---|---|---|
| Technical audit | Crawl brand, awareness, HCP and corporate domains; review indexing, rendering, gates and speed | A ranked fix list naming URLs and templates |
| Audience intent research | Map patient, caregiver, HCP and payer searches to existing and missing pages | An intent map with one target per page |
| Branded page optimization | Titles, headings, internal links and snippets written from approved claims | Review packets ready for MLR |
| Unbranded content | Condition hubs and question pages for patients and caregivers | Drafts with references for medical review |
| HCP content findability | Gate behavior, HTML prescribing information, clinical data pages | HCP pages that load and index correctly |
| Structured data | MedicalWebPage, audience, reviewer and review date markup | Validated markup on each template |
| International setup | Hreflang, country selectors, local review routes | A market-by-market plan |
| Reporting | Organic visits and actions by audience and page type | A monthly report with a dated change log |
Pharma SEO services for agencies
Healthcare agencies bring us in when they need SEO for pharmaceutical industry clients while their own teams run creative and media. We work under the agency’s name or alongside it, inside its review tooling, and hand over everything we produce.
Pharma website SEO for manufacturers with many domains
Large portfolios run separate product, awareness, HCP and corporate sites, often built by different vendors. We start with one crawl of the whole estate so duplicate content, broken cross-links and orphaned products show up together.
How SEO work moves through medical, legal and regulatory review
SEO changes are submitted to MLR as complete packets: the rendered page, the title tag, the meta description, image alt text and structured data, each claim tied to its reference. Reviewers approve once, and nothing goes live that they have not seen.
What counts as a change
Anything a searcher can read: visible copy, the title tag that appears in results, the meta description, alt text, link anchors and the text inside structured data. Brand teams are sometimes surprised that markup counts; reviewers usually are not.
Writing from an approved claim library
Many brands keep a library of approved claims with their references. Drafting search copy from that library means most edits reuse wording reviewers already know, and only genuinely new statements need fresh scrutiny.
Submission timing is the client’s call
Under 21 CFR 314.81(b)(3)(i), applicants submit promotional labeling and advertisements at the time of initial dissemination or publication, with Form FDA 2253. Your regulatory team decides what that means for each change; our packets give them the material in the form they need.
Advisory comments before launch
OPDP’s FAQs note that pre-approval of promotional materials is not required except in rare instances, and that the office gives opinions on proposed pieces when an applicant asks. Launch sites sometimes go that route; we build the schedule around it.
Keeping the calendar moving
We batch changes so reviewers see a quarter’s work in a few sittings, flag which items reuse approved language, and keep a running log of what is waiting, approved or live.
Brand site traffic flat while review cycles eat the calendar?Send the brand or corporate domain and the audiences that matter most. A free proposal follows with the search gaps we would close first and how each change would reach your reviewers.
Title tags, snippets and safety information in search results
A search result is a small piece of promotional real estate the brand does not fully control, because Google can rewrite titles and pick its own snippet text. We write titles and descriptions that stay safe even when shortened or replaced.
What FDA’s character-space draft guidance covers
FDA’s June 2014 draft guidance on platforms with character space limitations covers microblog posts and online paid search sponsored links, and it says product websites are outside its scope. For those formats it recommends that a benefit claim carry risk information in the same communication, plus a link to fuller risk information.
Organic titles and descriptions
Organic results are not sponsored links, but the same caution helps: we keep benefit claims out of titles and descriptions on branded pages, describe what the page offers instead, and let the page itself carry the balanced presentation.
When Google rewrites the snippet
If Google pulls a sentence from the page into the result, that sentence came from approved copy. We check live results after each release and adjust headings or page order when a rewrite pulls text out of context.
| Element | Risk | How we write it |
|---|---|---|
| Title tag | A benefit claim shown without risk context | Product and page purpose, no efficacy wording |
| Meta description | Truncated mid-sentence on phones | One complete sentence describing the page |
| Site name | Brand name shown without indication | Agreed with reviewers for each domain |
| Image results | Product imagery separated from the page | Alt text that describes, never claims |
| Sitelinks | Deep pages surfaced out of order | Clear structure so safety pages are reachable |
Indication, safety information and prescribing information page patterns
Branded pages need the indication near the top, safety information that a crawler can read, and prescribing information that loads without a dead end. We build templates once so every page inherits the pattern.
Safety information a crawler can read
Important safety information delivered as an image, or loaded only after a script runs, is invisible to some crawlers and assistive technology. We keep it in the HTML, in the reading order reviewers approved, on every template that names the product.
Prescribing information as HTML and PDF
Many brands publish prescribing information only as a PDF. Where reviewers agree, an HTML version of the same content helps clinicians on phones and gives search engines something they can parse; the PDF stays available.
Matching the official label
The National Library of Medicine’s DailyMed describes itself as the official provider of FDA drug label information. Clinicians compare against it, so brand pages and HTML prescribing information must match the current label exactly.
| Element | Pattern we use | SEO consideration |
|---|---|---|
| Indication statement | Near the top of every product page | Indexed text, not part of a hero image |
| Safety information | In the HTML, in the approved order | Readable by crawlers and screen readers |
| Prescribing information | PDF plus approved HTML version | Linked from every page in plain text |
| Patient information | Separate page or PDF as labeled | Clear title so patients find it |
| Footnotes and references | Numbered, linked to sources | Supports expertise signals |
| Region notice | For US residents only, or as reviewers set | Paired with hreflang for other countries |
Structured data for pharmaceutical and medical content
Structured data tells search engines what a page is about, who it is for and who reviewed it. We use it to describe pages accurately, not to add claims, and every property passes through the same review as the copy.
| Page type | Schema type | Properties that matter |
|---|---|---|
| Disease-awareness article | MedicalWebPage | medicalAudience, reviewedBy, lastReviewed, about |
| HCP clinical page | MedicalWebPage | medicalAudience set to Clinician, reviewedBy, lastReviewed |
| Corporate site | Organization | name, logo, sameAs, contact points |
| Pipeline or research page | WebPage with about | Investigational name only as reviewers allow |
| Questions page | FAQPage where eligible | Answers identical to the visible text |
| Newsroom | NewsArticle | datePublished, author, publisher |
Audience markup
Schema.org’s MedicalWebPage type has a medicalAudience property, and its MedicalAudienceType enumeration lists Clinician and MedicalResearcher. Marking HCP pages for clinicians and patient pages for patients keeps the intent of each page explicit.
Reviewer and review date
The reviewedBy and lastReviewed properties record who checked a page and when. They should name a real reviewer and a real date, and they should change only when the page is reviewed again.
Markup is not a claim channel
Descriptions inside markup are read by search engines and sometimes shown to people, so they follow the same claim rules as the page. We never place efficacy language in markup that the visible page does not carry.
E-E-A-T for drug and disease content: reviewers, references and dates
Google’s guidance on helpful, reliable content says its systems give extra weight to strong E-E-A-T on topics that could significantly affect people’s health, and that trust is the most important of those qualities. For pharmaceutical pages, trust is shown through named reviewers, references and visible review dates.
Named medical reviewers
Google encourages accurate bylines where readers expect them and treats fabricated creator profiles as deceptive. A reviewer line with a real name, credentials and role tells patients and clinicians who stands behind the page.
References people can follow
Statements about a condition or a product link to labels, guidelines and peer-reviewed publications. References belong in the footnotes reviewers already require; we make sure they are crawlable links rather than images of text.
Review dates and update cadence
Label updates, new indications and new safety information change pages. A visible review date and a recorded schedule of re-review keep pages current, and the dates in markup match the dates on the page.
Experience without patient stories that overreach
Patient stories can show real experience, but they carry the same balance and typical-result concerns as any other promotional content. We place them only where reviewers approve and never let them stand in for clinical information.
HCP-gated content, consent banners and other technical issues on regulated sites
Regulated sites add layers that ordinary sites lack: HCP confirmation screens, country notices, consent tools and heavy brand templates. Each can stop crawlers or slow people down, and each has a fix that keeps the safeguard in place.
Gated HCP pages that should be indexed
When clinical content sits behind a registration or confirmation step and you still want it indexed, Google’s paywalled content markup exists to separate legitimate gated content from cloaking. It applies when users must register for access, and it marks the gated section with isAccessibleForFree set to false.
Confirmation screens that do not block everything
An “Are you a healthcare professional?” interstitial is common on HCP sites. We make sure it does not replace the page for crawlers, does not trap patients who land from search, and offers a clear route to the patient site.
Consent tools and analytics
Consent banners should not cover the main content or block rendering. Analytics run only as consented, and nothing that could identify a patient’s condition is sent to analytics or advertising platforms.
Rendering, speed and old campaign microsites
Brand sites built around video and animation often render late. We check what a crawler sees, trim scripts on key templates, and consolidate or redirect retired campaign domains so their links are not wasted. Moves are handled with our website migration services team.
International pharmaceutical SEO: country labels, hreflang and local rules
Products are approved, labeled and promoted country by country, so international pharmaceutical SEO starts with which audiences each country site may address. Hreflang then connects the right versions without blending labels from different markets.
| Market | Rule we work from | What it means for search content |
|---|---|---|
| United States | 21 CFR 202.1 and FDA promotion rules | Branded patient pages possible, with balance and safety information |
| European Union | Article 88 of Directive 2001/83/EC | No promotion of prescription-only products to the general public; HCP and unbranded content instead |
| United Kingdom | Human Medicines Regulations 2012, regulation 284; ABPI Code | No advertising likely to lead to use of a prescription-only medicine by the public |
The EU and UK positions
Article 88 of Directive 2001/83/EC requires member states to prohibit advertising to the general public of medicines available on prescription only. In the UK, regulation 284 of the Human Medicines Regulations 2012 says a person may not publish an advertisement likely to lead to the use of a prescription-only medicine, and MHRA’s Blue Guide sets out how advertising rules are applied.
Industry codes
In the UK, industry promotion also follows the ABPI Code of Practice, now in its 2024 edition, which covers digital advertising and sits alongside PMCPA social media guidance. Local affiliates in each country usually own the review.
Hreflang with return links
Google’s localized versions guidance says each language version must list itself and every other version, uses ISO 639-1 language codes with optional ISO 3166-1 region codes, and reserves x-default for a fallback such as a country selector. On pharma estates we map country sites carefully, because two countries sharing a language may carry different labels.
Wider multi-country search programs are covered by our international SEO agency page, and translated site builds by our multilingual website design team. Nothing here is legal or regulatory advice; your regulatory and legal teams decide what each market allows.
Launching a new indication or a disease-awareness site?Tell us the launch window and which pages are already approved. We reply with a free proposal covering structure, review packets and the crawl checks we run before go-live.
Clinical trial, pipeline and publication pages
Trial and pipeline pages answer searches from patients looking for studies, clinicians referring them, investors and journalists. They carry no claims of safety or effectiveness for investigational products, and they point to the official registry record.
Trial pages that match the registry
Under 42 CFR 11.24, the responsible party registers an applicable clinical trial no later than 21 calendar days after the first participant is enrolled. A sponsor’s own study page should repeat the registry’s identifier, status and locations exactly, and be updated when the record changes.
Recruitment pages
Study recruitment pages need plain eligibility summaries, locations and a contact route that collects only what the study team needs. They are written for adults, and pediatric studies address parents and guardians.
Pipeline and publication pages
Pipeline pages list programs by stage and therapeutic area; publication pages list congress presentations and papers for clinicians. Both rank for company and research searches when they are crawlable HTML rather than slide images.
Pharma SEO compliance: the rules we work inside
We build search content inside the promotion rules that apply to your products and markets, and your reviewers have the final word. The table summarizes the rules that most often shape the work; it is general information, not legal advice.
| Rule or guidance | What it governs | Effect on SEO work |
|---|---|---|
| 21 CFR 202.1 | Content of prescription drug advertisements, including brief summary and fair balance | Branded copy, titles and markup written inside balance rules |
| 21 CFR 314.81(b)(3)(i) | Submission of promotional labeling and advertisements with Form FDA 2253 | Review packets give regulatory teams what they file |
| OPDP FAQs | Pre-approval exceptions, advisory comments, reminder ads | Launch schedules allow for optional advisory review |
| FDA June 2014 draft guidance on character space limits | Microblogs and paid search sponsored links | Caution carried over to organic titles and descriptions |
| Directive 2001/83/EC, Article 88 | Advertising to the public in the EU | No public promotion of prescription-only products |
| Human Medicines Regulations 2012, regulation 284; ABPI Code 2024 | Advertising to the public and industry promotion in the UK | HCP and unbranded content; local affiliate review |
| 42 CFR Part 11 | Registration of applicable clinical trials | Study pages mirror the registry record |
What we will not write
Some content stays off every page we touch, whatever the search opportunity.
- Uses outside the approved labeling
- Comparative claims reviewers have not approved
- Medical advice or dosing guidance for individual patients
- Content aimed at minors
- Any claim about an investigational product’s safety or effectiveness
- Copy without a reference for each product statement
Adverse event reports that arrive through search
Comments, reviews and contact forms on brand properties can surface reports of side effects. We route anything that might be one to your pharmacovigilance process the same day and never answer it ourselves.
AI answers: how patients, clinicians and analysts ask assistants about medicines
Patients ask ChatGPT, Claude, Perplexity, Gemini, Copilot and Google’s AI Overviews what a condition means and which treatments exist; clinicians ask about dosing and trial data; analysts ask about pipelines. Assistants lean on labels, registries, guidelines and pages they can read and check.
What assistants tend to cite
For clinical questions, official label sources, professional bodies and established medical publishers; for company questions, corporate newsrooms, registries and financial filings. Brand pages are cited when they state approved facts plainly and match the label.
What a brand should publish
Crawlable HTML safety and prescribing information, condition pages with named reviewers, trial pages that match the registry and a corporate site that answers company questions directly. Google states there are no additional requirements to appear in AI Overviews or AI Mode beyond being indexed and eligible for a snippet.
Prompt tracking, citation monitoring and assistant-specific work are covered in depth on our AEO for pharma companies page; this page stays with organic search.
Measuring organic performance for a regulated brand
We report organic visits and actions by audience and page type, with no health information collected along the way. Rankings appear as context, never as the headline.
| Measure | What it shows | Where it comes from |
|---|---|---|
| Organic visits by audience | Patients, caregivers and HCPs reaching their pages | Analytics segmented by site section |
| Search impressions and clicks | Visibility for condition, product and clinical searches | Google Search Console |
| HCP confirmations from search | Clinicians passing the gate after an organic visit | Gate events without personal data |
| Program enrollments started | Patients beginning support or savings enrollment | Conversion events, no health details |
| Prescribing information views | Clinician interest in full label content | Downloads and HTML page views |
| Indexed pages by type | Coverage of branded, awareness and HCP content | Search Console page indexing report |
| Review cycle time | Days from packet to approval | Shared change log |
Analytics without health data
Event names, page paths and form fields are checked so that nothing reveals a person’s condition. Our marketing analytics agency team sets this up when it is not already in place.
Separating branded demand from SEO gains
Product name searches rise with launches, television and field activity. We report non-branded and branded search separately so SEO is credited only with what it moved.
How long does SEO take for a pharma brand?
Technical fixes that need no new claims can show in Search Console within weeks of the next crawl. New pages wait on review, so most programs see steady gains across two to three quarters.
| Phase | What happens | Measure we report |
|---|---|---|
| Weeks 1 to 3 | Estate crawl, intent map by audience, claim library review | Indexed pages by type and audience gaps |
| Weeks 4 to 6 | Technical fixes: rendering, gates, speed, redirects | Crawl errors and field speed per template |
| Weeks 7 to 12 | First review packets for titles, snippets and markup | Packets approved and live |
| Months 4 to 5 | New unbranded and HCP pages through review | Impressions for condition and clinical searches |
| Month 6 | Audience-level report and the next quarter’s packets | Organic visits and actions by audience |
What slows a program down
Review queues, label updates that reopen approved pages, and launches that freeze the site. We plan around them by keeping a backlog of technical work that needs no new claims.
How much do pharmaceutical SEO services cost?
Our published SEO retainers run from $1,500 to $2,500 a month for a small program, $2,500 to $5,000 for a mid-size one, $5,000 to $10,000 for large sites, and $10,000 or more for multi-market and multi-site estates. A quote follows a written scope.
| Engagement | Price | What it usually suits |
|---|---|---|
| Free initial audit | $0 | A first read of one domain before any commitment |
| Technical SEO audit | From $1,900 | A brand or corporate site that needs a ranked fix list |
| Keyword research and mapping | From $1,200 | An intent map by audience for one product or condition |
| Migration support with redirect mapping | From $3,200 | Consolidating campaign microsites or replatforming a brand site |
| Analytics and conversion tracking implementation | From $2,400 | Audience reporting with no health data collected |
| Retainer, small | $1,500 to $2,500 a month | One brand site, one market |
| Retainer, mid | $2,500 to $5,000 a month | Patient and HCP sites with ongoing content |
| Retainer, large | $5,000 to $10,000 a month | Several brands or a large corporate estate |
| Retainer, enterprise | $10,000 or more a month | Multi-market, multi-site portfolios |
What moves the price
The number of domains, audiences and markets, how much new content needs review, and whether we prepare review packets or your agency does. Review time inside your company is not billed by us, but it shapes the schedule.
One-off projects or a retainer?
Audits, migrations and analytics setup suit fixed projects. Content on both tracks, review packets and monthly monitoring suit a retainer. Our SEO pricing guide explains how we scope each.
How to choose a pharmaceutical SEO company
Choose a provider that asks about your review process, your audiences and your label before it talks about keywords, and that leaves every account and file in your name. A pharma SEO agency worth hiring can show you a review packet, not just a ranking report.
| Requirement | How to check it |
|---|---|
| Works inside MLR review | Ask to see the format of a review packet and who prepares it |
| Separates branded and unbranded tracks | Ask how they would link an awareness hub to a product site |
| Knows safety information patterns | Ask how they keep safety information crawlable on every template |
| Handles gated HCP content | Ask how they would index clinical pages behind a confirmation step |
| Keeps health data out of analytics | Ask which events and parameters they would never collect |
| Plans international sites | Ask how they map hreflang where two countries share a language but not a label |
| Escalates adverse events | Ask how a possible side-effect report found in comments reaches pharmacovigilance |
| Leaves you in control | Confirm Search Console, analytics and content stay in your accounts |
Questions for the first call
Which of our pages would you change first, and what would reviewers need to see? Which searches would you leave alone? How do you report progress when a launch makes branded traffic jump?
Red flags
Ranking guarantees, link packages, copy drafted without references, plans that ignore safety information, and reporting that mixes branded and non-branded search.
Consultant or agency for a pharma brand?
A pharma SEO consultant suits a brand team with in-house writers and developers that needs direction and review-ready briefs. An agency suits teams that need the packets, pages and fixes produced as well.
Related services for pharmaceutical brands
Organic search is one part of how a pharmaceutical brand is found. These pages cover the rest.
- Paid search and programmatic campaigns for pharma brands
- AEO for pharma: visibility in AI assistants
- Life sciences marketing for research and lab suppliers
- Pharma branding agency for names and identity
- Choosing a partner for pharma marketing
- Healthcare SEO agency for practices, clinics and hospitals
- Marketing for retail pharmacies
- SEO services and retainers
- Medical device marketing agency
- Medical marketing agency
- Healthcare advertising agency
- Healthcare public relations
- Healthcare website design
- Technical SEO agency
- Enterprise SEO agency for large estates
- International SEO agency
- SEO audit service
- SEO content writing service
- Digital PR agency
- Marketing analytics agency
- Website migration services
Get a pharmaceutical SEO plan your reviewers can approve
Send the domains, the audiences that matter and how your review process works. We will reply with a free proposal and a written scope.
Getting found in search
AI, AEO and what is changing
Paid media and lead generation
Websites and design
Choosing and working with an agency
Software and app development
Website design by industry and type
Web development, platforms and hosting
Social, content and brand
By industry and by situation
Frequently asked questions
What is pharma SEO and who does it serve?
What are the best pharma SEO companies good at?
Who should pharmaceutical companies market to?
Who do pharma companies sell to?
How is SEO for pharma different from SEO for other industries?
How does SEO fit inside MLR review?
Do title tags and meta descriptions need regulatory review?
Do we need separate sites for healthcare professionals and patients?
Can HCP-only content behind a confirmation screen rank?
What is unbranded disease-awareness content, and why does it matter for search?
Can a pharmaceutical brand site rank for its own product name?
What structured data do pharmaceutical pages use?
How do you handle E-E-A-T on drug and disease pages?
How do you approach search for pharma brands in the EU and UK?
Will you work alongside the healthcare agency that already runs our brand?
How do you keep patient health data out of SEO reporting?
What happens if a comment or review on our site mentions a side effect?
Do you write content about specific drugs?
Do you do SEO for clinical trial and pipeline pages?
What should a brand team budget for a pharmaceutical SEO company?
Is organic search worth it for a pharma brand that already runs paid search?
Our brand team is outside New York. Can you still run our search program?
Brand site traffic flat while review cycles eat the calendar?Send the brand or corporate domain and the audiences that matter most. A free proposal follows with the search gaps we would close first and how each change would reach your reviewers.
Get a free marketing proposal
Tell us what you are trying to grow and we will come back with a plan, not a pitch deck. Same-day reply on weekdays.